Dewpoint secures $60M for condensates-drugging platform

January 31st, 2019 | BioWorld

Dewpoint Therapeutics Inc., a U.S.-German startup working to industrialize the drugging of biomolecular condensates – membraneless compartments found inside cells – has launched with a $60 million series A led by its founding investor, Polaris Partners. Samsara Biocapital, 6 Dimensions Capital, Ecor1 Capital, Alexandria Venture Investments and Bayer AG’s Leaps investment arm also participated. If successful, the company could open new avenues to working with transcription factors and RNA in cancer, neurodegenerative disorders, immune diseases and other indications.

Full article